HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

R Scott Pearsall Selected Research

Hereditary Hemorrhagic Telangiectasia

8/2011Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


R Scott Pearsall Research Topics

Disease

3Pulmonary Arterial Hypertension
12/2022 - 11/2016
3Neoplasms (Cancer)
07/2016 - 10/2004
2Pulmonary Hypertension
01/2020 - 11/2016
2Colorectal Neoplasms (Colorectal Cancer)
01/2020 - 12/2005
2Osteogenesis Imperfecta (Lobstein Disease)
10/2018 - 01/2018
2Anemia
06/2014 - 04/2014
2Osteoporosis
06/2012 - 04/2010
2Bone Resorption
06/2012 - 04/2010
1Inflammation (Inflammations)
12/2022
1Muscle Weakness
01/2021
1Vascular Diseases (Vascular Disease)
01/2020
1Neuromuscular Diseases (Neuromuscular Disease)
01/2019
1Congenital Abnormalities (Deformity)
11/2018
1Hypoxia (Hypoxemia)
11/2016
1Vascular Remodeling
11/2016
1Necrosis
07/2016
1Renal Cell Carcinoma (Grawitz Tumor)
07/2016
1Hypertrophy
01/2016
1Breast Neoplasms (Breast Cancer)
06/2015
1Carcinoma (Carcinomatosis)
06/2015
1Neoplasm Metastasis (Metastasis)
06/2015
1beta-Thalassemia (Cooley's Anemia)
06/2014
1Splenomegaly
06/2014
1Thalassemia
06/2014
1Hemolysis
06/2014
1Iron Overload
06/2014
1Hyperplasia
04/2014
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
04/2014
1Pre-Eclampsia (Preeclampsia)
08/2011
1Hereditary Hemorrhagic Telangiectasia
08/2011
1Carcinogenesis
12/2005
1Herpes Zoster
02/2005

Drug/Important Bio-Agent (IBA)

6Activins (Activin)IBA
12/2022 - 06/2015
5Transforming Growth Factors (Transforming Growth Factor)IBA
01/2020 - 04/2014
4LigandsIBA
01/2019 - 04/2014
3activin receptor type II-BIBA
10/2018 - 06/2014
2ACE-011IBA
12/2022 - 04/2010
2Proteins (Proteins, Gene)FDA Link
12/2022 - 04/2010
2Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA
01/2020 - 08/2011
2AzoxymethaneIBA
01/2020 - 12/2005
2FollistatinIBA
01/2019 - 11/2018
2Phosphotransferases (Kinase)IBA
11/2016 - 06/2015
2ErythropoietinFDA Link
06/2014 - 04/2014
2luspaterceptIBA
06/2014 - 04/2014
2Activin Receptors (Activin Receptor)IBA
06/2014 - 06/2012
1Growth Differentiation FactorsIBA
12/2022
1activin receptor type II-A (activin A receptor, type II)IBA
12/2022
1DystrophinIBA
01/2021
1Biomarkers (Surrogate Marker)IBA
01/2020
1activin AIBA
01/2020
1Glycoproteins (Glycoprotein)IBA
01/2019
1Collagen Type I (Type I Collagen)IBA
10/2018
1alpha2 Subunit Collagen Type IIBA
10/2018
1MonocrotalineIBA
11/2016
1Semaxinib (SU5416)IBA
11/2016
1Plasminogen Activators (Plasminogen Activator)IBA
11/2016
1human ALK1-Fc fusion proteinIBA
07/2016
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
07/2016
1Sunitinib (Sutent)FDA Link
07/2016
1MyostatinIBA
01/2016
1IronIBA
06/2014
1GlobinsIBA
06/2014
1Reactive Oxygen Species (Oxygen Radicals)IBA
06/2014
1Bone Density Conservation AgentsIBA
06/2012
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2011
1Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
08/2011
1EndoglinIBA
08/2011
1Transforming Growth Factor alpha (TGF-alpha)IBA
02/2005
1Epidermal Growth Factor (EGF)IBA
10/2004
1Dextran SulfateIBA
10/2004
1EpiregulinIBA
10/2004

Therapy/Procedure

2Therapeutics
01/2021 - 06/2012
1Intramuscular Injections
11/2018
1Drug Therapy (Chemotherapy)
06/2015
1Diet Therapy (Therapy, Diet)
12/2005
1Oral Administration
10/2004